Profile
Mr. James M.
Gower is Chairman & Chief Executive Officer at Rigel Pharmaceuticals, Inc. and an Advisor at VantagePoint Capital Partners.
Mr. Gower was previously employed as President & Chief Executive Officer by Tularik, Inc., Senior Vice President by Genentech, Inc., Vice President-Marketing by American Hospital Supply Corp., and President by Genentech Development Corp.
He also served on the board at Cell Genesys, Inc.
Mr. Gower received a BS and an MBA in Operations Research from the University of Tennessee.
Former positions of James M. Gower
| Companies | Position | End |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Chief Executive Officer | 2014-11-20 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Director/Board Member | 2009-10-13 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 1996-02-29 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 1990-12-31 |
| American Hospital Supply Corp. | Sales & Marketing | 1980-12-31 |
Training of James M. Gower
| University of Tennessee | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
| American Hospital Supply Corp. | Health Technology |
VantagePoint Management, Inc.
 VantagePoint Management, Inc. Investment ManagersFinance VantagePoint Management, Inc. (VantagePoint) is a venture capital firm founded in 1996 by Alan Edward Salzman, James D. Marver. The firm is headquartered in Santa Barbara, California with additional office in Beijing, China. | Finance |
| Genentech Development Corp. |
- Stock Market
- Insiders
- James M. Gower